-
EP3784701
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3784701
| EP3784701 - BLOOD-BRAIN BARRIER TRANSMIGRATING THERAPEUTIC COMPOUNDS AND USES THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 19.04.2024 Database last updated on 31.05.2024 | |
| Former | Request for examination was made Status updated on 29.01.2021 | ||
| Former | The international publication has been made Status updated on 02.11.2019 | Most recent event Tooltip | 23.04.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states National Research Council of Canada 1200 Montreal Road Ottawa, Ontario K1A 0R6 / CA | [2021/09] | Inventor(s) | 01 /
FANG, Hung 1099 Pegasus Crescent Ottawa, Ontario K4P 1P1 / CA | 02 /
STANIMIROVIC, Danica 6892 Sparkling Lake Way Ottawa, Ontario K4P 1R7 / CA | 03 /
HAQQANI, Arsalan 766 Fletcher Circle Kanata, Ontario K2T 0A8 / CA | 04 /
COSTAIN, Will 1850 Haig Dr. Ottawa, Ontario K1G 2J4 / CA | 05 /
HUSSACK, Gregory 131 Holland Avenue, Unit 510 Ottawa, Ontario K1Y 3A2 / CA | [2021/19] |
| Former [2021/09] | 01 /
FANG, Hung 1099 Pegasus Crescent Ottawa, Ontario K4P 1P1 / CA | ||
| 02 /
STANIMIROVIC, Danica 6892 Sparkling Lake Way Ottawa, Ontario K4P 1R7 / CA | |||
| 03 /
HAQQANI, Arsalan 766 Fletcher Circle Kanata, Ontario K2T 0A8 / CA | |||
| 04 /
COSTAIN, Will 1850 Haig Dr. Ottawa, Ontario K1G 2J4 / CA | |||
| 05 /
HUSSACK, Gregory 7-160 Bruyere Street Ottawa, Ontario K1N 5E1 / CA | Representative(s) | Fleuchaus & Gallo Partnerschaft mbB Steinerstraße 15/A 81369 München / DE | [N/P] |
| Former [2021/09] | Fleuchaus, Andrea, et al Fleuchaus & Gallo Partnerschaft mbB Patentanwälte Steinerstraße 15/Haus A 81369 München / DE | Application number, filing date | 19792686.8 | 23.04.2019 | [2021/09] | WO2019CA50499 | Priority number, date | US201862661869P | 24.04.2018 Original published format: US 201862661869 P | [2021/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019204912 | Date: | 31.10.2019 | Language: | EN | [2019/44] | Type: | A1 Application with search report | No.: | EP3784701 | Date: | 03.03.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 31.10.2019 takes the place of the publication of the European patent application. | [2021/09] | Search report(s) | International search report - published on: | CA | 31.10.2019 | (Supplementary) European search report - dispatched on: | EP | 06.05.2022 | Classification | IPC: | A61K47/68, A61P3/00, C07K14/765, C07K16/18, C07K16/28, C07K19/00, C12N5/10, C12N9/16, C12N9/24, C12N15/62 | [2022/23] | CPC: |
A61K47/6843 (EP,US);
C07K16/2863 (EP,US);
A61P21/00 (US);
A61P3/00 (EP);
C07K14/765 (EP,US);
C07K16/18 (EP);
C12N9/16 (EP);
C12N9/2402 (EP);
C12Y301/06013 (EP);
C12Y302/01045 (EP);
A61K2039/505 (EP,US);
A61K38/00 (EP);
A61K9/0019 (US);
C07K2317/14 (EP);
C07K2317/21 (EP);
C07K2317/33 (EP);
C07K2317/41 (EP);
C07K2317/569 (EP);
C07K2317/90 (EP);
C07K2317/92 (EP);
C07K2319/01 (EP);
|
| Former IPC [2021/09] | C07K19/00, A61K47/68, A61P3/00, C07K14/765, C07K16/00, C07K16/18, C07K16/28, C12N15/62, C12N5/10, C12N9/16, C12N9/24 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/09] | Title | German: | DIE BLUT-HIRN-SCHRANKE TRANSMIGRIERENDE THERAPEUTISCHE VERBINDUNGEN UND VERWENDUNGEN DAVON | [2021/09] | English: | BLOOD-BRAIN BARRIER TRANSMIGRATING THERAPEUTIC COMPOUNDS AND USES THEREOF | [2021/09] | French: | COMPOSÉS THÉRAPEUTIQUES FRANCHISSANT LA BARRIÈRE HÉMATO-ENCÉPHALIQUE ET LEURS UTILISATIONS | [2021/09] | Entry into regional phase | 24.11.2020 | National basic fee paid | 24.11.2020 | Search fee paid | 24.11.2020 | Designation fee(s) paid | 24.11.2020 | Examination fee paid | Examination procedure | 24.11.2020 | Examination requested [2021/09] | 23.11.2022 | Amendment by applicant (claims and/or description) | 22.04.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 26.04.2021 | Renewal fee patent year 03 | 25.04.2022 | Renewal fee patent year 04 | 12.04.2023 | Renewal fee patent year 05 | 15.04.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2015131258 (NAT RES COUNCIL CANADA [CA]) [Y] 1-15 * page 4, lines 7-12; figure 8; sequences 1-3 *; | [Y]WO2015191934 (ABBVIE INC [US], et al) [Y] 1-15 * sequences 153-155 *; | [Y]WO2018031424 (OSSIANIX INC [US]) [Y] 1-15 * figure 25 *; | [Y] - Qing-Hui Zhou ET AL, "Brain-Penetrating IgG-Iduronate 2-Sulfatase Fusion Protein for the Mouse", Drug Metabolism and Disposition, doi:10.1124/dmd.111.042903, (20120201), pages 329 - 335, URL: http://dmd.aspetjournals.org/content/40/2/329.full.pdf#page=1&view=FitH, (20160107), XP055239284 [Y] 1-15 * table 5 * DOI: http://dx.doi.org/10.1124/dmd.111.042903 | [Y] - KAN SHIH-HSIN ET AL, "Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of alpha-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts", BIOCHEMICAL JOURNAL, PUBLISHED BY PORTLAND PRESS ON BEHALF OF THE BIOCHEMICAL SOCIETY, GB, (20140301), vol. 458, no. Part 2, doi:10.1042/BJ20130845, ISSN 0264-6021, pages 281 - 289, XP009177918 [Y] 1-15 * figure 7 * DOI: http://dx.doi.org/10.1042/BJ20130845 | [A] - DANICA B STANIMIROVIC ET AL, "Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics", EXPERT OPINION ON DRUG DISCOVERY, London, GB, (20141112), vol. 10, no. 2, doi:10.1517/17460441.2015.974545, ISSN 1746-0441, pages 141 - 155, XP055395138 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1517/17460441.2015.974545 | [T] - TERSTAPPEN GEORG C ET AL, "Strategies for delivering therapeutics across the blood-brain barrier", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 20, no. 5, doi:10.1038/S41573-021-00139-Y, ISSN 1474-1776, (20210301), pages 362 - 383, (20210301), XP037444970 [T] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/s41573-021-00139-y | [A] - RUBEN J. BOADO ET AL, "Insulin Receptor Antibody-Sulfamidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells", MOLECULAR PHARMACEUTICS, US, (20140804), vol. 11, no. 8, doi:10.1021/mp500258p, ISSN 1543-8384, pages 2928 - 2934, XP055406273 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1021/mp500258p | [A] - ABULROB A ET AL, "The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells", JOURNAL OF NEUROCHEMISTRY, WILEY-BLACKWELL PUBLISHING LTD, GB, (20051101), vol. 95, no. 4, doi:10.1111/J.1471-4159.2005.03463.X, ISSN 0022-3042, pages 1201 - 1214, XP003010699 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1111/j.1471-4159.2005.03463.x | International search | [XY]WO2011044542 (ARMAGEN TECHNOLOGIES INC [US], et al) [X] 1, 3, 6-16, 21, 22, 24, 26, 27, 29, 30, and 32-34 * See entire document, SEQ ID NO: 9 * [Y] 17-19; | [XY]WO2015131256 (NAT RES COUNCIL CANADA [CA]) [X] 2-6, 9-11, 21, 23, 25, 26, 28, 29, and 31-34 * See entire document, SEQ ID NO: 4 * [Y] 17-19; | [XY]WO2018007950 (NAT RES COUNCIL CANADA [CA]) [X] 2-6, 9-11, 21, 23, 25, 26, 28, 29, and 31-34 * See entire document, SEQ ID NO: 9 * [Y] 17-19; | [Y] - HENRY, K.A. et al., "Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing", Protein Engineering, Design & Selection, (20150827), vol. 28, no. 10, ISSN 1741-0134, pages 379 - 83, XP055648915 [Y] 17-19 * See entire document, Tables I-III R28, M79 * DOI: http://dx.doi.org/10.1093/protein/gzv039 |